Welcome to our dedicated page for Cheelcare news (Ticker: CHCRF), a resource for investors and traders seeking the latest updates and insights on Cheelcare stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cheelcare's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cheelcare's position in the market.
Cheelcare (OTC: CHCRF) will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. The company presentation is scheduled for Wednesday, April 22, 2026 at 3:30 PM ET.
CEO Eugene Cherny and VP of Growth Allan Boyd will deliver the presentation and hold one-on-one investor meetings during the conference.
Cheelcare (OTC: CHCRF) delivered its first Curio robotic complex‑rehab power wheelchairs to paying customers on April 9, 2026, marking a move into commercial production and initial revenue generation for its flagship platform.
The company also reported record Companion unit sales in March, growing Medicare and Medicaid reimbursement uptake, an expanding RFQ pipeline, and a new ~16,000 sq. ft. manufacturing facility and assembly line to support scalable production.
Cheelcare (OTC: CHCRF) reported Q3 fiscal results for the quarter ended January 31, 2026, with revenue of $549,857 (16% year-over-year) and net loss of $509,824. Gross margin improved to 44.3%. Key operational wins include U.S. HCPCS reimbursement for Companion, PDAC verification, Health Canada "Compliant" rating, 2,000 cumulative Companion units sold and distribution through over 500 dealer locations. Cash was $83,642 with working capital of $355,047; the company completed a $1.0 million unsecured promissory note financing on February 18, 2026 to support working capital and manufacturing scale-up.
Cheelcare (CHCRF) closed a $1.0 million unsecured note financing on February 18, 2026 by issuing 12% promissory notes. Pathfinder purchased $750,000 and NameSilo purchased $250,000. Notes mature August 11, 2027, are redeemable after one year, and pay semi-annual interest.
The company issued 132,450 bonus shares to lenders equal to 20% of principal at $1.51 per share; proceeds will fund working capital, inventory, manufacturing, and general corporate purposes.
Cheelcare (TSXV: CHER) entered term sheets for a non-brokered unsecured note financing of up to $1,000,000, expected to include $750,000 from Pathfinder Asset Management Ltd. and $250,000 from NameSilo Technologies.
The Notes carry an 18-month term at 12% annual interest, with interest payable semi-annually and principal due at maturity. The company may redeem after one year without penalty. Cheelcare will issue an aggregate 132,450 Bonus Shares (20% of principal over $1.51/share) subject to a four-month hold. Closing remains subject to customary corporate and Exchange approvals.